Search Results
Seeking support from romantic partners
The purpose of this study is to determine whether and how people's perceptions of the power in their romantic relationships shape the messages they use to seek support from their romantic partners.
Have you sought comfort, advice, information, esteem boosts, or emotional support from your romantic partner within the last 4 weeks?
People who are not in a romantic relationship
People who did not seek support from their romantic partner in the last 4 weeks.
People who do not have access to technology to compete the survey.
Nicotine absorption, toxicant exposure, and subjective effects of a heat-not burn tobacco product
The purpose of this study is to evaluate the nicotine delivery, toxicant exposure, and subjective effects associated with the use of heat-not burn tobacco products, compared with electronic cigarettes.
Participants will attend 2 clinic visits at the Penn State Milton S. Hershey Medical Center lasting approximately 1 ½ hours each. Participants will be asked to refrain from using any tobacco or nicotine products for at least 14 hours prior to each visit. During the visit participants will try the new tobacco products in the study center while blood samples are collected through an IV catheter placed in the arm.
120
Current daily cigarette smoker (5 or more per day)
History of a seizure disorder or had a seizure in the past 12 months
History of difficulty providing or unwilling to provide blood samples
Current user of an IQOS device
Current user of an electronic cigarette device
PSCI 24-013 A RANDOMIZED PHASE II, DOUBLE-BLIND, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF AUTOGENE CEVUMERAN PLUS NIVOLUMAB VERSUS NIVOLUMAB AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE UROTHELIAL CARCINOMA
This trial is looking at what happens to muscle invasive bladder cancer when adding cevumeran to Nivolumab
Participants will be required to keep all study appointments, tell the study doctor about all medications they are taking, report any side effects to the study doctor.
$202 for each visit completed
Surgical resection of muscle-invasive UC of the bladder or upper tract
Cisplatin ineligible
Absence of residual disease and absence of metastasis,
ECOG performance status of 0 or 1
Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment
Any prior neoadjuvant immunotherapy
Adjuvant chemotherapy or radiation therapy for UC following surgical resection
Absence of spleen
Measuring the impact of three types of resistant starch on fecal butyrate levels and the gut microbiome in healthy and obese individuals
This is dietary intervention trial that will examine the impact of consuming three different types of resistant starch on the gut microbiome and butyrate levels in normal weight and obese individuals. Participants will consume starch samples daily for 24 weeks, collecting weekly fecal samples that will be returned to the lab. Researchers will analyze the bacterial fermentation products in these samples, particularly butyrate and analyze the microbiome composition. This will allow identification of differences in resistant starch (a dietary fiber) processing between normal weight and obese individuals and will also determine if the three resistant starches tested have differing impacts on the microbiome and butyrate levels.
Diagnosis of Diabetes
Pregnant
Taking antibiotics
Phase 2 Study of Bladder-SparIng ChemoradiatioN with Durvalumab (PSCI# 19-072) (EA8185)
The purpose of this study is to compare the usual treatment of chemotherapy and radiation to adding MEDI4736 (durvalumab) immunotherapy to the usual treatment. The addition of MEDI4736 (durvalumab) immunotherapy to the usual treatment may help shrink your cancer better than the current standard of care or usual approach for bladder cancer. But, it could also cause side effects, which are described in the risks section.This study will help determine if this different approach is better than the usual approach. To decide if it is better, the study doctors will be looking to see if the study approach increases the life of patients by 6 months or more compared to the usual approach.
If you decide to take part in this study, you will either get chemotherapy and radiation for 6-8 weeks, or you will get durvalumab immunotherapy in addition to chemotherapy and radiation for 6.5-8 weeks. After you finish your study treatment, your doctor will continue to follow you for up to 3 years. The follow-up will consist of visits to his or her office and CT scans of the bladder.
Patient must have histologically proven pure or mixed urothelial cancer of the bladder.
Patient must be ≥ 18 years of age.
Must have adequate renal function as evidenced by calculated (Cockcroft’s formula) creatinine clearance or 24 hours actual creatinine clearance ≥ 30mL/min.
Patient must have a life expectancy of at least 12 weeks, as determined by the treating physician.
Patient must not have received any previous radiation therapy to the pelvic area.
Women must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.
Patients with a negative biopsy of nodes determined to be suspicious on imaging are not eligible.
Small cell carcinoma is excluded, however other variant histologies are permitted provided a component of urothelial carcinoma is present.
A Multicenter, Open-Label, Single Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis: Open Label, 64 weeks study. Injectable medicine. Males/Females 2-11 years with moderate to severe atopic dermatitis. The goal of the study is assess the uptake of the drug by the body and safety of nemolizumab administered with topical corticosteroids.
Participants will attend in person visit at the Dermatology Clinical Trial office. Dr. Zaenglein is the pediatric dermatologist in charge of this research study and will do all skin evaluations. In addition at different time points there will be blood that is drawn, questionnaires to be completed, and ECGs will be performed.
Study coordinator will discuss.
Diagnosed with Moderate to Severe Atopic Dermatitis
Willing to attend all study visits and follow directions
Had a documented asthma exacerbation requiring hospitalization in the past 12 months.
Weigh less than 22 pounds
A PHASE 2, MULTICENTER, PLACEBO-CONTROLLED,RANDOMIZED, DOUBLE-BLIND, 48-WEEK STUDY TOEVALUATE THE EFFICACY AND SAFETY OF COMBINATIONTHERAPY OF K-877-ER AND CSG452 IN PATIENTS WITHNONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH)WITH LIVER FIBROSIS
This is a Phase 2, multicenter, double-blind, randomized, 52-week study to assess the efficacy and safety of K-001 medication compared with placebo in subjects with noncirrhotic NASH with liver fibrosis. This study will look at a study drug, called K-001, for participants with a liver condition called noncirrhotic nonalcoholic steatohepatitis (NASH). This condition is defined by a build-up of fat in the liver, which causes liver damage and inflammation. Due to this damage, the liver does not work as well. If left untreated, NASH can lead to liver fibrosis (scarring of the liver), liver cancer, or liver failure. K-001 is a once daily pill that contains combination of two medicines: K-877-ER and CSG452. The purpose of the study is to find out whether the study drug works and how safe it is in participants diagnosed with NASH with liver fibrosis. To answer these questions, the study drug will be compared with a placebo.
There will be 10 in person visits over 52-week study period. Various procedures will be completed such as a fibroscan, ECG, liver MRI, liver biopsy, blood draws. You will be randomly assigned by chance (like the flip of a coin) to receive the study drugs or placebo (inactive substance). You will be taking a pill once daily.
$1310
NASH diagnosis
Stage 1, 2 or 3 fibrosis
Chronic alcohol or drug abuse
Cirrhosis
History of liver transplant, or subjects listed for liver transplantation
Inability to provide informed consent
Interaction between cocoa and the fecal microbiome
There is a growing body of data demonstrating that polyphenols from foods including cocoa and chocolate are metabolized by the gut microbiome to produce small molecular weight metabolites that have greater systemic bioavailability and a potential role in the health-related effects of the parent compounds. The objective of this protocol is to collect fecal samples from human subjects, aged 18 - 40 years old, with overweight or obesity (BMI = 25 – 40 kg/m2), to use as a source of gut microbiota. These fecal samples will be used in in vitro fermentation experiments where fecal samples will be mixed cocoa powder or cocoa extracts in buffer. Samples from these fermentation experiments will be analyzed by chemical methods to identify the metabolites present and will be tested in bioassays to determine potential health-related bioactivities. Because biological sex can impact the composition of the microbiome, we plan to recruit both biological males and females.
There will be two in-person visits. Screening and consent collection will be done at the first and participants will receive supplies for stool collection. The participant will collect the stool samples at home and then return the sample at the second visit.
25
BMI of greater than 25 to 40 kg/m2
Free of chronic intestinal/colon diseases
Willingness to abstain from consumption of polyphenol-rich foods for 24 h
Proficiency with English (verbal and written)
Pre-existing chronic gastrointestinal diseases
Use of antibiotics within 30 days
Medical circumstances that prevent participation
Mental wellbeing during the Covid-19 pandemic: a study of essential workers and social media use
Through in-depth interviews, we examine how the Covid-19 pandemic has impacted the daily lives and mental well-being of essential workers, as well as their use of social media.
Social media users (e.g. Twitter, Instagram, Facebook)
Adults 18 or older
Social media users
those working from home during the Covid-19 pandemic
minors (those under 18)
those who do NOT use social media
A Phase III double-blind, randomised, placebo-controlled trial toevaluate liver-related clinical outcomes and safety of once weeklyinjected survodutide in participants with compensated nonalcoholicsteatohepatitis/metabolic dysfunction associatedsteatohepatitis (NASH/MASH) cirrhosis
This is Phase III study to test whether survodutide (BI 456906) helps people with a liver disease called NASH/MASH who have cirrhosis. The purpose of the study is to find out whether the study drug works and how safe it is in participants diagnosed with MASH and liver cirrhosis over a long-term treatment. To answer these questions, the study drug will be compared with a placebo. The overall study duration is approximately 4.5 years.
If you enroll in this study, you will undergo a series of testing. You will be asked to complete an initial assessment that includes a physical exam, vital signs, waist circumference, height, and weight measurements, questionnaires, blood draws, ECG, fibroscan, eye examination, and pregnancy test, if applicable, liver biopsy (if applicable). You will be randomized to either Survodutide once weekly or placebo (an inactive substance of no medical value). For treatment, you will be trained to inject yourself once a week with the study medicine. There will be up to 28 in person visits over 4.5 years study duration - to re-supply the study drug and copmlete safety testing. There will be up to 16 phone calls with the study staff.
up to $3,800 over 4,5 years
MASH/NASH diagnosis
Cirrhosis
Fibrosis stage 4
BMI ≥27 kg/m2 (≥25 kg/m2 for Asian trial participants)
Chronic alcohol or drug abuse
History of liver transplantation or listed for liver transplantation
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma
The purpose of this study is to determine how effective and safe axi-cel is compared to standard of care, specifically chemo-immunotherapies, and use this information to determine the best choice of treatment in Subjects with Relapsed/Refractory Follicular Lymphoma
Attend all study visits receive study drug or SOChave blood drawn for various testsECHO or MUGA, ECG, PET/CT, and MRI if neededbone marrow biopsy if neededComplete questionnaires
R/r disease as defined as one of the following options: a) First-line systemic chemoimmunotherapy and high-risk disease, defined as relapse or progression within 24 months of initiation of the initial course of chemoimmunotherapy (ie, POD24)
Clinical indication for treatment local symptoms due to progressive or bulky disease, systemic B symptoms, compromised organ function due to disease progression, cytopenias due to marrow involvement, or symptomatic extranodal disease.
At least 1 measurable lesion per the Lugano Classification
No known history or suspicion of central nervous system (CNS) lymphoma involvement
FL Grade 3b
Small lymphocytic lymphoma
Lymphoplasmacytic lymphoma
Full-thickness involvement of the gastric wall by lymphoma
Exploring the feasibility of mobile eye-tracking to study informed consent in older adults
The study will explore the feasibility of using mobile eye-tracking hardware to study how older adults read an informed consent document. The primary objectives are to: (1) characterize gaze (eye-movements) of participants reading a standardized informed consent document using non-invasive mobile eye-tracking hardware, (2) conduct interviews with participants discuss how they read and understood the informed consent document, and (3) evaluate the associations between the data sources to describe how older adults read and understood the informed consent document. Participants will read an informed consent document on a computer on which an eye-tracker is mounted. After reading the document participants will answer surveys related to demographic information, health literacy, and experience with the hardware. They will then complete an interview in which they are asked about their experience reading the informed consent document.
There will be 1 in person visit. During the visit you will be asked to read an informed consent document on a computer screen. You will then answer questions about the consent document, complete an interview about the informed consent document, and complete surveys about your demographic information, health literacy, and experience participating in the study.
$60
able to provide consent
able to read and speak english
have the following eye conditions: cataracts, nystagmus, eyelid ptosis, amblyopia, strabismus
history of cognitive impairment that impairs capacity to consent
Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis
Restrictive (vs liberal) fluid treatment strategy during the first 24 hours of resuscitation for sepsis-induced hypotension will reduce 90-day in-hospital mortality.
Suspected or confirmed infection
Sepsis induced hypotension
> 3 L intravenous fluids
Pregnancy
Severe volume depletion
Immediate surgical intervention planned
Opioid Use and Criminal Justice: Intervening to Improve the Outcomes of Women
The new program will help women who have recently been involved in the criminal justice system and use opioids (heroin, fentanyl, prescription pain medications nonmedically) to join treatment programs for opioid addiction. The program will also assist women in finding and getting access to the social services they may need and provide opioid response training. Half of the recruited participants will be randomly selected to be in a trauma support group for women with addiction issues. The program will also help women with common barriers to staying in treatment, such as childcare and transportation.
Participants will be connected to drug treatment programs that offer medications to stop or reduce drug use. Participants will be assigned a peer recovery specialist; these are women in long-term recovery who will help the enrolled women with transportation, childcare, and completing any tasks they may have due to criminal justice involvement or child welfare. Half of our participants will be assigned to a support group of other women in recovery. Participants will complete surveys at three time points and will be paid $50 each time. Participants will also be given overdose response training and take-home-naloxone.
$575
Use heroin, fentanyl, or prescription opioids without a prescription
interested in medications to reduce opioid use
18 years or older
live in Harrisburg area
not female
not older than 17
Smart Connected Water Bottle and Lighting Devices: A Prenatal Pilot Study
We will conduct a pilot study to test feasibility of an innovative light device and blue-light glasses for promoting better sleep and a novel, smart water bottle for proper hydration. We will also examine women’s sleep and hydration behaviors in relation to their perceptions of pain, and obtain feedback from the participants on the overall patient intervention content to reduce prescription opioid use and promote behavioral pain management strategies after delivery.
Currently recruiting pregnant women who are in their 2nd or 3rd trimester.Attend a pre-session (in person OR remote) to explain the use of the water bottle, lighting devices, activity monitors, and weight scaleUse the devices for 22 days and complete surveys in your own homeAttend a post-session (in person OR remote) to return devices and participate an interview about the last 22 days
$100
2nd or 3rd trimester
18-45
Reside around State College, PA
Diagnosed eating disorders/extreme dietary restrictions
Currently diagnosed with gestational diabetes
Currently diagnosed with pre-eclampsia
Not pregnant
The Effects of Aircraft Seat Width on Passenger Comfort
The objective of this research is to determine the relationship between aircraft seat width and passenger comfort. Airlines are reducing the sizes of seats and improving their ability to fly planes at or near capacity. The combined effect is to decrease the quality of the experience of passengers. This work will help us to understand the degree to which comfort has been reduced.
You must be a healthy adult aged 18 years or older.
PSCI 21-158 Radiopaque Hydrogel Rectal Spacer for Prostate Cancer Radiation Image Guidance
Prior to enrollment, potential subjects will be evaluated during the Screening Period to determine eligibility. The following assessments will be performed during the Screening Period:●Review of eligibility ●Placement of hydrogel spacer and fiducial marker after eligibility is determined Visit 2 or Day 2 or Post-test - Radiotherapy per standard of care.
Prior to enrollment, potential subjects will be evaluated during the Screening Period to determine eligibility. The following assessments will be performed during the Screening Period:●Review of eligibility ●Placement of hydrogel spacer and fiducial marker after eligibility is determinedVisit 2 or Day 2 or Post-test - radiotherapy per standard of care
N/A
N/A
N/A
N/A
Prior prostate surgery
Prior prostate radiotherapy
N/A
N/A
Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients with Nonalcoholic Steatohepatitis
This study will be a pilot study to evaluate the workability, safety and acceptability of Exercise and Liver FITness (EL-FIT), a mHealth exercise training program previously confirmed in patients with cirrhosis,(1) in patients with Nonalcoholic Steatohepatitis (NASH)
El-Fit NASH (Nonalcoholic Steatohepatitis) is a 9-week intervention trial for patients with NASH. Our goal is to evaluate the workability, safety and acceptability of Exercise and Liver FITness (EL-FIT), a mHealth exercise training program. The El-FIT application allows for participants to access to a library of guided workouts. All patients will be asked to complete a screening visit that includes a physical exam, height, and weight measurements & surveys. Participants will be asked to download the EL-Fit NASH application and use it for 8 weeks. In addition to using the application, participants will be asked to complete 3 check-in phone calls through-out the 8 weeks.
Evidence of NASH
Posission of a Smart Phone
Active or recent participation in exercise training program within the last 90 years
Active or recent weight-loss supplement use within the last 90 days
Active illicit substance use
Cancer that is active
PSCI 24-077 A Phase 1b/2 Study Assessing the Safety and Efficacy of Evexomostat (SDX-7320) in Combination with a PI3K Pathway Inhibitor plus Fulvestrant in Postmenopausal Women with Advanced Breast Cancer and PI3K Pathway Alterations Who Have Progressed on or Following Endocrine Therapy plus a CDK4/6 Inhibitor
this trial is looking at introducing a medication to control blood sugars elevations caused by CDK inhibitors.
Participants must agree to come to all study visits, report any new medications to the study team, agree to having blood work done at least 8-12 hours after eating something, take study medication as directed.
Patient with histologically and/or cytologically confirmed diagnosis of HR+, HER2- breast cancer, as determined by the local laboratory.
Patient has identified PI3K pathway
Patient has locally advanced (not amenable to curative therapy or metastatic) breast cancer meeting any of the following categories:
Patient has measurable disease
Patient has known primary brain malignancy,
Patient has a known hypersensitivity to evexomostat, fulvestrant, alpelisib or capivasertib, or to any of their excipients.
Patient has had major surgery within 30 days
Patient has uncontrolled human immunodeficiency virus (HIV) infection.
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer (NRG-BR004) (PSCI# 20-136)
The purpose of this study is to compare the usual treatment plus placebo to the usual treatment plus atezolizumab. The addition of atezolizumab to the usual treatment could stabilize your cancer. This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if the atezolizumab lengthens the time during and after the treatment of your cancer that you live with your cancer and it is stable. Atezolizumab is already approved by the FDA for use in non-small cell lung cancer and urinary cancer. Its use in this study is considered experimental. There will be about 600 people taking part in this study.
pt will initially get the chemotherapy drug paclitaxel or docetaxel along with trastuzumab, pertuzumab, and either placebo or atezolizumab.
Histologically confirmed adenocarcinoma of the breast with locally recurrent, unresectable disease, or metastatic disease
Adequate hematologic function within 14 days prior to randomization
Localized palliative radiation therapy is allowed for symptom management if completed 14 days or more prior to randomization
Adequate renal function determined within 14 days prior to randomization
History of exposure to cumulative doses of doxorubicin greater than 360 mg per square meter of body surface area or its equivalent
Prior treatment with mTOR inhibitors or CDK 4/6 inhibitors in combination with endocrine therapy for treatment of metastatic disease
History of asymptomatic LVEF decline to < 40% during or after prior HER2-targeted therapy
Prior treatment with CD137 agonists or immune checkpoint-blockade therapies, including antiCD40, anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies
Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin
The purpose of this study is to compare any good and bad effects of usual radiation plus the study treatment drug (durvalumab), to the usual therapy of radiation plus the drug (cetuximab) in patients with head and neck cancer who cannot take the drug cisplatin.
The purpose of this study is to compare any good and bad effects of usual radiation plus the study treatment drug (durvalumab), to the usual therapy of radiation plus the drug (cetuximab) in patients with head and neck cancer who cannot take the drug cisplatin.
18 or older
Adequate hematologic function
Adequate hepatic function
Adequate renal function
Prior radiotherapy
Prior immunotherapy
Major surgery within 28 days prior to Step 1 registration
Uncontrolled hypertension
Hand Action and Perception in Parkinson's Disease
The purpose of this research study is 1.) to determine if Parkinson’s Disease (PD) causes changes in the way that people sense the movements of and forces produced by their bodies, and to connect any of these changes in sensation to changes in the brain, and 2.) to identify how changes in movement might come from different parts of the nervous system. This study will use a combination of electromyography, via electrodes placed on the skin, and finger force recordings to infer how PD affects patients' sense of force production, and the neural mechanisms underlying this change.
This study requires a single in-person visit. We will use adhesive skin sensors on the forearms to measure muscle activity. At the same time, we test the participant's finger strength and then ask them to press with moderate force on piano-key-like sensors. Participants will be asked to match force levels between hands and to move an on-screen cursor into a target.
$40.00
No history of earning disability, neurodevelopmental disorder, seizures, multiple concussion (> 3), cerebrovascular disease, brain tumor, hydrocephalus, or any CNS disease other than PD.
No present carpal tunnel syndrome, cervical myelopathy, brachial plexopathy, hand pain, or another neuromusculoskeletal disorder affecting hand function
No history of alcohol and/or drug abuse.
Effects of fasting on blood protein levels
Up to 50 older adults (age 60+ years) will participate in a two-visit CRC study with blood sampling (40 ml per visit) occurring before and after a breakfast meal. Specifically, there will be four (10 ml) blood draws during each of the visits, with each blood draw timed one hour apart (T1 to T4). The two visits (short- and long-fasting) will be randomly assigned and counterbalanced for the order in which they occur and will occur at least a week apart. During the short-fasting visit, participants will arrive fasting and be given breakfast after the second blood draw (T2). During the long-fasting visit, participants will arrive fasting and be given breakfast after the fourth blood draw (T4). Aside from blood draws, and vitals obtained at the start of each visit, participants will be seated comfortably in a chair in a small room by themselves. They will be checked upon periodically to ensure they are not falling asleep, they are comfortable, etc. They will also be given a small packet of written questionnaires to complete after T1 and after T3 (i.e., after the 1st and 3rd blood draws). Each visit will be between 3.5 and 4 hours.
There will be two in-person visits both will include four blood draws.
$100 total
Fluent in English
Vaccinated for COVID-19
Having current severe psychiatric symptoms that interfere with testing
Alcohol or substance abuse, chronic medicinal use of opioids, glucocorticoids, anti-inflammatories, or active cancer treatment in the last 12 months
Examining the relationship between caregiving factors, social determinants of health, and quality of life among parental caregivers of adults with profound autism: A mixed methods study
This is a survey study that will examine factors that impact the quality of life for parental caregivers of an adult child with profound autism.
Participants will be asked to take a survey about their experiences caring for their autistic adult-child and questions about their well-being.
Primary parental caregiver for an adult-child (aged 18 and older) with profound autism
Reside in the United States
Able to read and understand English
Are able to provide informed consent
PSCI 23-012 THE JANUS RECTAL CANCER TRIAL: A RANDOMIZED PHASE II TRIAL TESTING THE EFFICACY OF TRIPLET VERSUS DOUBLET CHEMOTHERAPY TO ACHIEVE CLINICAL COMPLETE RESPONSE IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER
This trial is using long course chemoradiation in combination with three different chemotherapy treatments to treat rectal cancer. Once therapy is completed patients will either have surgery or watch and wait. The goal is to see which therapy is better in achieving a complete response, if any.
Patients will be expected to come to the clinic for all radiation treatments and all chemotherapy treatments.
Tumor Site: Rectum; ≤ 12cm from the anal verge
No prior systemic chemotherapy, targeted therapy, or immunotherapy; or radiation therapy administered as treatment for colorectal cancer within the past 5 years is allowed.
Not pregnant and not nursing,
Age ≥ 18 years
No recurrent rectal cancer; prior transanal excision, prior distal sigmoid cancer with a low anastomosis
No known mismatch repair deficient rectal adenocarcinoma
AWS-PSU: Active Women's Study at Penn State University
AWS-PSU: Active Women's Study at Penn State University This research study is being conducted to evaluate the impact of exercise and reproductive function on bone strength. Eligible young women (age 18-30) are those that are generally healthy and either a) exercising and experiencing regular or irregular menstrual cycles, or b) not exercising and experiencing regular menstrual cycles.
Age 18-30
BMI between 16-29.9
No hormonal contraception for 6 months
Currently using medication impacting bone
PLS Natural History Study
This study will provide a strong basis and foundation for future clinical trials that use historical controls. The study will collect clinical data and biological specimens to create a dataset and biorepository to be shared with other researchers as a foundation for future clinical trials.
This is a volunteer study for participants diagnosed with Primary Lateral Sclerosis (PLS) or suspected to have PLS by a neurologist. You will be expected to attend scheduled visits in person or by telephone, complete study testing and audio/video recordings. The study includes clinical measurements to assess disease status and motor function, a number of questionnaires, collection of biospecimens including DNA, blood, and urine, and an electromyography (EMG) test. There will be 6 visits over 24 months, of these 6 three will be in-person visits (2-3 hours) and the other three will be telephone calls (lasting about 45 minutes to an hour). Blood and urine samples will be collected during these visits.
$100 per in person visit (three) and $50 for telephone visit (three) completed.
Symptom onset was no more than 15 years prior to baseline
Ability to independently walk with or without an assistive device (e.g., walker) at the baseline evaluation
In cases where a molecular test has been done prior to enrollment in this study, HSP or HSP-related mutations are negative
Expected to have at least some bulbar symptoms (dysarthria, dysphagia, drooling or pseudobulbar affect); however, the absence of these symptoms will not exclude participants when molecular testing is negative for known HSP
UMN symptoms and signs only in the legs
Unwilling or unable to visit the study site asrequired
Clinically obvious cognitive impairment that precludes obtaining informed consent, as determined by the site PI
Participating in clinical treatment trials
Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC (EA5181) (PSCI# 21-041)
The purpose of this study is to compare the usual approach of chemo/radiation followed by one year of MEDI4736 (durvalumab) to chemo/radiation with MEDI4736 (durvalumab) followed by one year of MEDI4736 (durvalumab). The addition of MEDI4736 (durvalumab) during chemo/radiation could prevent your cancer from returning and extend your life. But, it could also cause side effects.This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if the study drug extends the life of patients and/or prevents the tumor from coming back as compared to the usual approach.This drug, MEDI4736 (durvalumab), is already approved by the FDA for use in other cancers, and for use in your type of cancer after the completion of chemotherapy and radiation. At this time MEDI4736 (durvalumab) is not yet approved (experimental) when given with chemotherapy and radiation. There will be about 660 people taking part in this study.
The purpose of this study is to compare the usual approach of chemo/radiation followed by one year of MEDI4736 (durvalumab) to chemo/radiation with MEDI4736 (durvalumab) followed by one year of MEDI4736 (durvalumab). The addition of MEDI4736 (durvalumab) during chemo/radiation could prevent your cancer from returning and extend your life. But, it could also cause side effects.This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if the study drug extends the life of patients and/or prevents the tumor from coming back as compared to the usual approach.This drug, MEDI4736 (durvalumab), is already approved by the FDA for use in other cancers, and for use in your type of cancer after the completion of chemotherapy and radiation. At this time MEDI4736 (durvalumab) is not yet approved (experimental) when given with chemotherapy and radiation. There will be about 660 people taking part in this study.
Patient must have an ECOG Performance Status of 0 or 1.
Body weight > 30 kg of patients.
Patient must not have unintentional weight loss > 10% within 30 days prior to registration.
Patient must have a baseline ECG obtained within 6 weeks of registration.
Patient must not have a history of active hepatitis B (chronic or acute) or hepatitis C infection.
Patient must not have a known active tuberculosis infection.
Patient must not have any severe infections within 4 weeks prior to registration including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia.
Patient must not have signs or symptoms of severe infection (sepsis) within 2 weeks prior registration.
CAREER: No Time to Explain: Developing Robots that Actively Prevent Overtrust during Emergencies
The overall goal of this proposal is to develop robots that can help people correctly calibrate their trust in the robot. We look at this problem within the context of robot-guided emergency evacuation. We believe that robots stationed inside of buildings can serve as instantaneous first responders helping people safely evacuate during an emergency, thus saving lives. Participants will be asked to interact with an emergency guidance robot and decide whether to follow the robot to an exit.
Reasonable ability to see
Cannot see or read the consent form
GPRPL Study
The purpose of this study is to find genetic causes of recurrent pregnancy loss (RPL). RPL is defined by two or more miscarriages under 20 weeks gestation and affects approximately 5% of women.The causes of RPL are not well understood. After all the currently recommended testing for RPL has been done, about half of women with RPL will still have no identifiable cause. This lack of knowledge makes it difficult to provide effective medical care for couples with RPL.This study will compare reading about 20000 genes in the entire human genetic library by whole genome sequencing in the miscarriage material and also your and your partner’s DNA from blood samples. The DNA in a person is a combination of the DNA from each of their biological parents. If you have healthy children we may ask your consent for them to give a blood sample for DNA extraction and testing. Similarly, we may ask the same for other family members such as grandparents if necessary. We may also request your permission to use stored DNA or miscarriage material from previous pregnancy loss if available. Testing of family members or previous miscarriage materials may help to understand DNA sequence variants or changes identified in the miscarriage sample.
There will be a one time collection of blood samples.
Two or more prior losses of clinically recognized pregnancies
Prior losses are unexplained